Remove 2026 Remove Chemotherapy Remove Dosage
article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.

FDA
article thumbnail

Apixaban vs warfarin: rise of newer anticoagulant

Druggist

Eliquis is still protected by patent rights in the UK, with exclusive availability rights until 2026 (IPO, 2021). . Additionally, the dosage is much simpler as compared to warfarin as it does not change generally after treatment initiation is completed. . Patients who have cancer or receive chemotherapy.